News

EHA 2025: AstraZeneca’s surovatamig is potential next-gen BiTE for R/R B-ALL
This trial evaluated the safety, tolerability, pharmacodynamics, pharmacokinetics and clinical activity of AstraZeneca’s ...
PMLive4h
AstraZeneca and CSPC Pharmaceuticals enter AI-driven partnership worth $5.3bn
AstraZeneca (AZ) and CSPC Pharmaceuticals Group have entered into a partnership worth up to $5.3bn to develop therapies for ...
The Pharma Letter5h
AstraZeneca’s Ultomiris shows strong OS in HSCT TMA
Initial results from the ALXN1210-TMA-314 Phase III trial showed that UK pharma major AstraZeneca’s Ultomiris (ravulizumab) ...
Fierce Pharma3d
AstraZeneca takes $181M hit in Syntimmune shareholder lawsuit on top of previous $130M award
For the second time in nine months, a Delaware judge has sided (PDF) with Syntimmune shareholders over AstraZeneca, granting a $181 million award. The decision comes on top of a $130 million verdict ...
KSL9d
AstraZeneca sues Utah attorney general over new Utah drug price law
The pharmaceutical drug company AstraZeneca filed a lawsuit against the Utah attorney general claiming Utah's new law on ...
AstraZeneca Unit Owes $180 Million-Plus in Syntimmune Case (1)
An AstraZeneca Plc affiliate suffered a greater than $180 million court loss Wednesday over its lackluster efforts to ...
Explore more
AstraZeneca sues Utah attorney general over new drug pricing law
AstraZeneca, a major pharmaceutical company, has sued Utah’s Attorney General Derek Brown over a recently passed state law ...
Fierce Pharma56m
AstraZeneca touts early Ultomiris survival data in children living with rare post-transplant complication
Now that Ultomiris has matched the indications of its predecessor Soliris, AstraZeneca is eyeing new avenues for the C5 drug ...